Encompass Health - EHC Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Encompass Health in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EHC shares.
View EHC analyst ratings or view top-rated stocks.

6 brokerages have issued 12-month price targets for Encompass Health's stock. Their EHC share price forecasts range from $58.00 to $72.00. On average, they expect the company's stock price to reach $64.13 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for EHC or view top-rated stocks among Wall Street analysts.

Encompass Health's stock was trading at $59.81 at the start of the year. Since then, EHC shares have increased by 2.5% and is now trading at $61.28.
View the best growth stocks for 2023 here.

Encompass Health saw a decrease in short interest in December. As of December 30th, there was short interest totaling 2,520,000 shares, a decrease of 8.4% from the December 15th total of 2,750,000 shares. Based on an average daily trading volume, of 684,500 shares, the short-interest ratio is presently 3.7 days. Approximately 2.6% of the shares of the company are short sold.
View Encompass Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our EHC earnings forecast.

Encompass Health will be holding an earnings conference call on Wednesday, February 8th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Encompass Health Co. (NYSE:EHC) released its quarterly earnings results on Wednesday, October, 27th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.03. The business had revenue of $1.28 billion for the quarter, compared to analysts' expectations of $1.31 billion. Encompass Health had a net margin of 5.39% and a trailing twelve-month return on equity of 15.59%. The business's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.78 EPS.

Encompass Health announced a quarterly dividend on Wednesday, October 19th. Stockholders of record on Tuesday, January 3rd will be paid a dividend of $0.15 per share on Tuesday, January 17th. This represents a $0.60 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Friday, December 30th.
Read our dividend analysis for EHC.

Encompass Health (NYSE:EHC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 0.98%. The dividend payout ratio is 22.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EHC will have a dividend payout ratio of 18.58% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EHC.

Encompass Health issued an update on its FY 2022 earnings guidance on Wednesday, November, 2nd. The company provided EPS guidance of $2.71-$2.86 for the period, compared to the consensus earnings per share estimate of $2.86. The company issued revenue guidance of $4.32 billion-$4.35 billion, compared to the consensus revenue estimate of $4.36 billion.

231 employees have rated Encompass Health Chief Executive Officer Mark Tarr on Glassdoor.com. Mark Tarr has an approval rating of 79% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Encompass Health investors own include Salesforce (CRM), Johnson & Johnson (JNJ), Alibaba Group (BABA), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), Cisco Systems (CSCO), Pfizer (PFE), Verizon Communications (VZ) and Advanced Micro Devices (AMD).

Encompass Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EHC."

Encompass Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.34%), Copeland Capital Management LLC (0.99%), Reinhart Partners Inc. (0.79%), Wedge Capital Management L L P NC (0.55%), Bernzott Capital Advisors (0.39%) and Fort Washington Investment Advisors Inc. OH (0.28%). Insiders that own company stock include Andrew L Price, Donald L Correll, Elissa Joy Charbonneau, Greg D Carmichael, Kevin J O'connor, Mark J Tarr and Terrance Williams.
View institutional ownership trends.

Shares of EHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EHC stock can currently be purchased for approximately $61.28.

Encompass Health (NYSE:EHC) has a market capitalization of $6.12 billion and generates $5.12 billion in revenue each year. The company earns $412.20 million in net income (profit) each year or $2.72 on an earnings per share basis.

The company employs 43,400 workers across the globe.

Encompass Health's mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The official website for the company is www.healthsouth.com. The company can be reached via phone at (205) 967-7116, via email at investorrelations@healthsouth.com, or via fax at 205-969-4719.